Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,775 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,528)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06228209 | Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer(TIER-PC) | recruiting | N/A | 60 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06716580 | EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations(EQUAL) | recruiting | N/A | 1,000 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 15, 2026 |
| clinicaltrials |
| NCT07405190 | Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC | recruiting | Phase 2 | 46 | Massachusetts General HospitalOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05889546 | Rapid Autopsy Protocol for Patients With Small Cell Lung Cancer | recruiting | — | 30 | Indiana UniversityOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06420206 | Goals of Care Discussion for Patients With Advanced Lung and Gastrointestinal Cancer in the Emergency Department of a Comprehensive Cancer Center | recruiting | N/A | 200 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | recruiting | Phase 2 | 75 | University of California, IrvineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06686771 | Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer(CURB2) | recruiting | Phase 3 | 320 | Canadian Cancer Trials GroupNETWORK | 2 | Jul 14, 2026 | clinicaltrials |
| NCT06896162 | PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival(PROGRESS) | recruiting | N/A | 500 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07416474 | RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC) | recruiting | Phase 3 | 574 | RemeGen Co., Ltd.INDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07613424 | A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)(Genomet) | recruiting | N/A | 1,000 | AstraZenecaINDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07669779 | A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer | recruiting | Phase 2 | 348 | AkesoINDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07689643 | Safety and Preliminary Efficacy of [177Lu]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic Non-Small Cell Lung Cancer | recruiting | Early Phase 1 | 36 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07703631 | Characterization, Health Resource Utilization and Biomarkers in Early-stage | recruiting | — | 267 | Hospital Universitario San IgnacioOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT04577599 | Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54 | recruiting | N/A | 1,160 | Wake Forest University Health SciencesOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04792489 | DALY II USA/ MB-CART2019.1 for DLBCL | recruiting | Phase 2 | 315 | Miltenyi Biomedicine GmbHINDUSTRY | 2 | Jul 13, 2026 | clinicaltrials |
| NCT05628376 | TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO | recruiting | — | 600 | University College, LondonOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06037954 | A Study of Mental Health Care in People With Cancer | recruiting | N/A | 130 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06427954 | Mobile Application to Improve Health-Related Outcomes in Patients With Advanced Lung Cancer(THRIVE) | recruiting | N/A | 250 | Massachusetts General HospitalOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07535437 | A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 66 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07699328 | A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer(REACH-EGFR) | recruiting | Phase 1 / Phase 2 | 315 | Voronoi, IncINDUSTRY | 10 | Jul 13, 2026 | clinicaltrials |
| NCT07699861 | LUCINAE Registry: Thoracic Cancers During Pregnancy(LUCINAE) | recruiting | — | 100 | Oncology Institute of Southern SwitzerlandOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05077527 | Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 20 | AIDS Malignancy ConsortiumNETWORK | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05672251 | Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 2 | 36 | City of Hope Medical CenterOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05985330 | Pilot Study of the Contribution of Fractional Exhaled Nitric Oxide as a Prognostic Marker of Response to Anti-PD-L1 Immunotherapy in Non-small Cell Lung Cancer(FENOTYPE) | recruiting | — | 56 | Centre Hospitalier Universitaire DijonOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06695845 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | recruiting | Phase 2 | 200 | Jazz PharmaceuticalsINDUSTRY | 3 | Jul 10, 2026 | clinicaltrials |
| NCT07355205 | First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer(FLINN) | recruiting | Phase 1 / Phase 2 | 26 | Washington University School of MedicineOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07452224 | ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer | recruiting | Phase 2 | 80 | iLeukon Therapeutics, Inc.INDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05937906 | Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.(IMMUNOMEK) | recruiting | Phase 1 / Phase 2 | 24 | Centre Georges Francois LeclercOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06825078 | Performance of Lung MRI Combined to Synthetic CT in the Follow-up of Lung Nodules(NODU-MR) | recruiting | N/A | 50 | University Hospital, BordeauxOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07174583 | A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 262 | IDEAYA BiosciencesINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT05543330 | A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC | recruiting | Phase 1 / Phase 2 | 116 | Wuhan YZY Biopharma Co., Ltd.INDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06103682 | LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)(OBLITERATE) | recruiting | N/A | 100 | University of California, DavisOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06139627 | Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy | recruiting | N/A | 180 | City of Hope Medical CenterOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07235098 | Effect of a Music Intervention in Reducing Distress and Pain in Patients With Lung Cancer Undergoing Mini-invasive Surgery | recruiting | N/A | 74 | Oncology Institute of Southern SwitzerlandOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07242547 | Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients(MERLIN) | recruiting | Phase 2 | 37 | Fundación GECPOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07296887 | CARE Tool Study Aim 3 | recruiting | N/A | 430 | Washington University School of MedicineOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07314216 | Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma | recruiting | Phase 2 | 15 | Hunan Cancer HospitalOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07416695 | A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC | recruiting | Phase 1 | 138 | Shanghai Henlius BiotechINDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT05424029 | Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer | recruiting | — | 200 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06552234 | Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC(REPOROS) | recruiting | Phase 2 | 30 | Centre Hospitalier Intercommunal de Toulon La Seyne sur MerOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06699979 | Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes | recruiting | — | 300 | Central South UniversityOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06996249 | Prospective Data Collection Initiative on Thoracic Malignancies(DuTOC) | recruiting | — | 12,000 | Dutch Society of Physicians for Pulmonology and TuberculosisOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07518160 | JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study | recruiting | Phase 2 | 35 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT04389632 | A Study of Sigvotatug Vedotin in Advanced Solid Tumors | recruiting | Phase 1 | 1,006 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 7 | Jul 6, 2026 | clinicaltrials |
| NCT07300150 | A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors | recruiting | Phase 1 | 210 | PAQ Therapeutics, Inc.INDUSTRY | 2 | Jul 6, 2026 | clinicaltrials |
| NCT07358676 | A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer | recruiting | Phase 2 | 25 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07423585 | Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer | recruiting | Phase 2 | 39 | Asrar AlahmadiOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07538804 | A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 294 | Avistone Biotechnology Co., Ltd.INDUSTRY | 2 | Jul 6, 2026 | clinicaltrials |
| NCT07645222 | PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC | recruiting | Phase 1 | 396 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06839105 | A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies | recruiting | Phase 1 | 214 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 2, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 15, 2026source: clinicaltrials